头颈癌药物市场按药物类别、销售管道和地区划分

头颈癌治疗市场规模预计在 2025 年达到 22.866 亿美元，预计到 2032 年将达到 37.445 亿美元，2025 年至 2032 年的年复合成长率（CAGR）为 7.3%。

头颈癌是一个医学术语，指发生在鼻腔、咽喉、鼻窦、喉头和口腔周围的各种恶性肿瘤。大多数头颈癌是鳞状细胞癌。如果及早发现，头颈癌的治癒率很高，但治疗效果取决于多种因素。

市场动态

头颈癌负担的增加、对疾病诊断的日益关注、吸烟、饮酒和重度饮酒的增加、对安全有效的药物和治疗的需求增加以及研发的增加是预计将促进全球头颈癌治疗市场增长的主要因素。

例如，2022年2月，辛辛那提大学的研究人员启动了一项新的临床试验，以检验局部放射疗法与免疫疗法相结合是否可以更好地治疗方法復发性头颈癌患者。

此外，2021年2月，美国FDA授予Kura Oncology公司开发的替比法尼（tipifarnib）突破性疗法认定，用于治疗头颈部鳞状细胞癌（HNSCC）。该药物是一种强效选择性口服药物。

本次调查的主要特点

• 本报告对全球头颈癌治疗市场进行了详细分析，并以 2024 年为基准年，提供了预测期 2025-2032 的市场规模（百万美元）和年复合成长率(CAGR)。
• 它还强调了各个领域的潜在商机，并说明了针对该市场的引人注目的投资提案。
• 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的主要考察。
• 该报告根据公司亮点、产品系列、关键亮点、财务业绩和策略等参数，对全球头颈癌药物市场的主要企业进行了概述。
• 本报告的见解将使负责人和企业经营团队能够就未来的产品发布、新兴车型、市场扩张和行销策略做出明智的决策。
• 全球头颈癌药物市场报告针对该行业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
• 透过用于分析全球头颈癌治疗市场的各种策略矩阵，相关人员将更容易做出决策。

目录

第一章：调查目标和先决条件

• 调查目的
• 先决条件
• 简称

第二章 市场展望

• 报告描述
  • 市场定义和范围
• 执行摘要
• Coherent Opportunity Map（COM）

第三章：市场动态、法规与趋势分析

• 市场动态
  • 头颈癌发生率不断上升
  • 头颈癌药物的副作用
  • 安全有效药物的需求不断增加
• 影响分析
• 主要亮点
• 监管情景
• 产品发布/核准
• PEST分析
• 波特分析
• 併购场景

4. 2020 年至 2032 年全球头颈癌药物市场（依药物类别）

• 化疗
• 免疫疗法
• 标靶治疗

5. 全球头颈癌药物市场依销售管道，2020-2032 年

• 医院药房
• 药局和药房
• 网路商店

6. 2020 年至 2032 年全球头颈癌药物市场（按地区）

• 北美洲
• 欧洲
• 亚太地区
• 拉丁美洲
• 中东和非洲

第七章 竞争态势

• Merck & Co., Inc.
• Eli Lilly and Company
• Bristol-Myers Squibb Company
• Astrazeneca Plc.
• Fresenius Medical Care AG & CO. KGAA
• F. Hoffmann-la Roche Ltd.（Genentech, Inc.）

第 8 章 章节

• 调查方法
• 关于出版商

Head and Neck Cancer Drugs Market is estimated to be valued at USD 2,286.6 Mn in 2025 and is expected to reach USD 3,744.5 Mn by 2032, growing at a compound annual growth rate (CAGR) of 7.3% from 2025 to 2032.

Head and neck cancer is a medical term used to describe different malignant tumors that develop in or around the nose, throat, sinuses, larynx, and mouth. Most head and neck cancers are squamous cell carcinomas. Head and neck cancer is highly curable if detected early, however, the treatment depends on a number of factors.

Market Dynamics

Growing burden of head and neck cancer, rise in focus on disease diagnosis, increase in cigarette smoking, alcohol consumption, and high use of tobacco, high demand for safe and effective drugs or treatment, and increasing research and development are major factors expected to augment the growth of the global head and neck cancer drugs market.

For instance, in February 2022, University of Cincinnati researchers launched a new clinical trial to examine if the combination of a localized radiation treatment and immunotherapy can be a better treatment for patients with recurrent head and neck cancer.

Moreover, in February 2021, the U.S. FDA granted breakthrough therapy designation to Tipifarnib developed by Kura Oncology, Inc., for the treatment of patients with head and neck squamous cell carcinoma (HNSCC). This is a potent, selective, and orally administered drug.

Key features of the study

• This report provides in-depth analysis of the global head and neck cancer drugs market, and provides market size (USD Mn) and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global head and neck cancer drugs market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Merck & Co., Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Astrazeneca Plc., Fresenius Medical Care AG & CO. KGAA, and F. Hoffmann-la Roche Ltd. (Genentech, Inc.,), among others.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global head and neck cancer drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global head and neck cancer drugs market.

Market Segmentation

• Global Head and Neck Cancer Drugs Market, By Drug Class
  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy
• Global Head and Neck Cancer Drugs Market, By Sales Channel
  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Stores
• Global Head and Neck Cancer Drugs Market, By Geography
  • North America
  • U.S.
  • Canada
  • Europe
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Company Profiles
  • Merck & Co., Inc.
  • Eli Lilly and Company
  • Bristol-Myers Squibb Company
  • Astrazeneca Plc.
  • Fresenius Medical Care AG & CO. KGAA
  • F.Hoffmann-la Roche Ltd. (Genentech, Inc.)

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Class
  • Market Snapshot, By Sales Channel
  • Market Snapshot, By Geography
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Increasing prevalence of head and neck cancer
  • Adverse effects of head and neck cancer drugs
  • Increasing demand for safe and effective drugs
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product launch/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Global Head and Neck Cancer Drugs Market, By Drug Class, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Chemotherapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(USD Mn)
• Immunotherapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(USD Mn)
• Targeted Therapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(USD Mn)

5. Global Head and Neck Cancer Drugs Market, By Sales Channel, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(USD Mn)
• Drug Stores & Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(USD Mn)
• Online Stores
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(USD Mn)

6. Global Head and Neck Cancer Drugs Market, By Geography, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Sales Channel, 2020-2032,(USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(USD Mn)
    • U.S.
    • Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Sales Channel, 2020-2032,(USD Mn) Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(USD Mn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Sales Channel, 2020-2032,(USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(USD Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Sales Channel, 2020-2032,(USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(USD Mn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Middle East and Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Sales Channel, 2020-2032,(USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(USD Mn)
    • GCC Countries
    • Israel
    • Rest of Middle East
    • South Africa
    • North Africa
    • Central Africa

7. Competitive Landscape

• Merck & Co., Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Eli Lilly and Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bristol-Myers Squibb Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Astrazeneca Plc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Fresenius Medical Care AG & CO. KGAA
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• F. Hoffmann-la Roche Ltd. (Genentech, Inc.)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Analyst Views

8. Section

• Research Methodology
• About us